Full Breakdown
FDA Allows Philip Morris’s Zyn Nicotine Pouches to Carry Modified-Risk Claim
6/30/2026, 11:30:08 PM
FDA Grants Modified-Risk Marketing for Zyn
On June 30, 2026, the FDA authorized Swedish Match, a Philip Morris International subsidiary, to market 20 Zyn nicotine-pouch products with a claim that switching from cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. Zyn pouches contain nicotine but no tobacco. They cover ten flavors in 3-mg and 6-mg nicotine strengths.
Policy Shift and Market Context
Zyn was cleared for sale in January 2025 without risk language. The June 2026 approval follows the Trump administration’s easing of flavored nicotine rules, a response to falling cigarette sales and the rapid rise of nicotine pouches as a “smoke-free” alternative.
Core Numbers
- 20 Zyn variants (10 flavors × 2 nicotine strengths).
- 794 million cans sold in 2025, double 2023 volume.
- FDA has cleared 26 nicotine-pouch products overall.
- 1.7 % of U.S. middle- and high-school students used nicotine pouches in 2025; Zyn was the most popular brand.
- About 45 million U.S. adults are legal-age nicotine consumers.
Agency and Industry Positions
Acting Center for Tobacco Products director Bret Koplow said the FDA’s scientific review showed the authorized Zyn products lower disease risk for adult smokers and that the labeling benefits public health, while requiring five-year post-market surveillance. PMI’s U.S. chief Stacey Kennedy called the ruling “an important moment for the more than 45 million legal-age nicotine consumers in America,” and CEO Jacek Olczak called the change a “net positive” for the category.
Health-Group Objections
The American Lung Association warned that nicotine pouches are not FDA-approved cessation aids and that flavored variants “attract kids.” Mike Seilback urged the agency to reverse the decision to protect children from lifelong nicotine addiction.
Divergent Assessments
The FDA notes no tobacco product is safe yet permits a reduced-risk claim for Zyn. PMI markets it as a safer alternative, but long-term health data on nicotine-pouch users are lacking, a gap the agency will monitor.
Implications
The ruling creates a precedent for modified-risk labeling of non-combustible tobacco, potentially reshaping the U.S. nicotine market, influencing smoker choices, and raising youth-use concerns.
Verbatim Quotes
- “FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices,” — Bret Koplow, Acting Director, FDA Center for Tobacco Products
- “It is appalling that the FDA would authorize flavors like citrus, cool mint and cinnamon as modified risk tobacco products, which attract kids,” — Mike Seilback, Assistant Vice President, American Lung Association
- “Today’s news ensures these adults have access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to Zyn reduces the risk of smoking-related diseases like heart disease and lung cancer,” — Stacey Kennedy, U.S. CEO, Philip Morris International
- “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” — FDA modified-risk claim
Future Monitoring
The FDA requires Swedish Match to conduct five-year post-market studies and may revoke the claim if youth use rises. Analysts expect more flavored-pouch petitions, while health advocates will press to limit youth exposure.
